A Promising Path Forward in Obesity Pharmacotherapy: Ecnoglutide and the Evolution of GLP-1R Agonist Design

Announcing a new article publication for BIO Integration journal.  This article reviews robust evidence from a large, multicenter, randomized, placebo-controlled study in Chinese adults with overweight or obesity, demonstrating dose-dependent and sustained weight loss of up to 15.4% over 48 weeks, alongside broad cardiometabolic improvements and an acceptable safety profile. The commentary underscores ecnoglutide’s mechanistic innovation—preferential cAMP signaling with reduced β-arrestin recruitment—which may enhance durability of effect and tolerability compared with existing GLP-1 therapies, while also situating the findings within the global context of rising obesity prevalence and the need for population-specific data. By integrating clinical efficacy, mechanistic insight, and regional relevance, this publication positions ecnoglutide as a promising next-generation candidate in the evolving landscape of precision obesity treatment.

Read More: https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2025-0129

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

Please visit www.bio-integration.org to learn more about the journal.

Editorial Board: https://bio-integration.org/editorial-board/

BIOI is available on the ScienceOpen platform (https://www.scienceopen.com/search#collection/55f45bac-fd64-431c-9fe7-50fd6a7f8781).

Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).

ISSN 2712-0074

eISSN 2712-0082

Liangbin Zhou, Pingyu Jin and Dongze Wu et al. A Promising Path Forward in Obesity Pharmacotherapy: Ecnoglutide and the Evolution of GLP-1R Agonist Design. BIOI. 2025. Vol. 6(1). DOI: 10.15212/bioi-2025-0129